Search Blog
Categories
August 2019
M T W T F S S
« Jul    
 1234
567891011
12131415161718
19202122232425
262728293031  

Tags

Vivera Pharmaceuticals’ Chief Medical Officer Dr. Stephen J. McColgan Appointed Clinical Instructor At University of California, Riverside, School of Medicine

newsfilecorp

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6166/46933_5acf6485b486abb3_001.jpg

Newport Beach, California–(Newsfile Corp. – August 14, 2019) –

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6166/46933_5acf6485b486abb3_001full.jpg

About Vivera Pharmaceuticals, Inc.

Vivera Pharmaceuticals, Inc. is an innovative, science-driven pharmaceutical company focused on opioid deterrence and cessation and non-addictive solutions for pain management.

In addition to its pharmaceutical and medical device products, the company has global exclusivity to license the patented and patent-pending TABMELT™ sublingual drug-delivery system for the pharmaceutical use of cannabinoid compounds.

Vivera Pharmaceuticals is seeking to conduct case studies and clinical trials on CBD in the TABMELT™ drug delivery format with the goal of gaining FDA approval for its products.

The company is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.

For more information, visit https://viverapharmaceuticals.com.

Investor Relations Inquiries:
thinkHERO
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.
416-526-9911
investorrelations@viverapharma.com

Press Inquiries:
thinkHERO
Karin Elz, for Vivera Pharmaceuticals, Inc.
416-992-9848
press@viverapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46933